Friday, August 21, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

The scientist using AI to hunt for antibiotics just about everywhere

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The scientist using AI to hunt for antibiotics just about everywhere Date: 2026-02-16 11:00 Source: https://www.technologyreview.com/2026/02/16/1132516/cesar-de-la-fuente-using-ai-antibiotics-hunt/ <p>When he was just a teenager trying to decide what to do with his life, César…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • These peptides haven't yet been transformed into usable drugs that help people

    80% confidence

  • It's only been a few years since folks have been using AI meaningfully in drug discovery

    80% confidence

  • The use, overuse, and misuse of antibiotics drives antimicrobial resistance

    80% confidence

  • De la Fuente is marvelously talented, very innovative

    80% confidence

  • De la Fuente has really helped pioneer the space of harnessing AI for real-world problems

    80% confidence

  • Drug discovery in any domain is a statistics game. You need enough shots on goal to happen to get one

    80% confidence

  • This is the world that we live in today, and it's incredible

    80% confidence

  • AI has already saved decades of human research time

    80% confidence

  • Antimicrobial resistance deaths could surge past 8 million by 2050

    80% confidence

  • Many companies that attempted antibiotic development have folded because there's no good return on investment

    80% confidence

  • Researchers have moved from using predictive models to developing generative approaches

    80% confidence

  • Antimicrobial resistance is an almost impossible problem

    80% confidence

  • The world of antibiotic development needs as much creativity and innovation as researchers can muster

    80% confidence

  • The antibiotic discovery pipeline remains perilously thin, impeded by high development costs, lengthy timelines, and low returns on investment

    80% confidence

  • Biology is an information source like a bunch of code

    80% confidence

Cited in these Via News reports